An Open-Label, Phase 2, Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus Participating in Extension Protocols 217-102, 103, or 104
Pfizer's Exubera® was intended to provide a novel inhaled insulin delivery method for diabetes management. However, the product was withdrawn from the market due to poor commercial performance rather than safety concerns. The termination of this long-term safety study indicates a strategic pivot away from inhaled insulin therapies, suggesting limited future market potential for similar products. Competitors in the diabetes space may capitalize on this gap, focusing on alternative delivery methods or formulations. Diligence should consider the evolving landscape of diabetes management and the potential for inhaled therapies to regain interest with advancements in formulation technology.
Indication: Diabetes Mellitus
Modality: small molecule
Target: Inhaled insulin (Exubera®) for the treatment of Type 1 and Type 2 Diabetes Mellitus.
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Inhaled insulin (Exubera®) for the treatment of Type 1 and Type 2 Diabetes Mellitus.
View original source fields
Condition raw: Diabetes Mellitus
Condition normalized: Diabetes Mellitus
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Inhaled insulin (Exubera®) for the treatment of Type 1 and Type 2 Diabetes Mellitus.
Target normalized: Inhaled insulin (Exubera®) for the treatment of Type 1 and Type 2 Diabetes Mellitus.